Transcatheter Cardiovascular Therapeutics (TCT)

The Transcatheter Cardiovascular Therapeutics (TCT) conference is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the largest conference focused on interventional cardiovascular medicine. TCT includes seminars on all areas of intervention cardiology, structural heart, vascular in interventions, peripheral artery disease, and other procedures in the cath lab.

RSS icon
The Boston Scientific Acurate neo2,. Abbott Portico and the new Edwards Sapien X4 TAVR valves were hot topics of discussion at TCT 2022. #TVT #TVT22 #TVT2022

VIDEO: TAVR's long-term impact on patient care

One thing was clear at TVT 2022 in Chicago: TAVR's popularity over surgery is changing the way physicians think about patient care. 

A TAVR procedure being performed at Northwestern Medicine in Chicago. These structural heart procedures require a team approach.

VIDEO: How to build a structural heart program

Charles Davidson, MD, clinical chief of cardiology and medical director of the Bluhm Cardiovascular Institute, Northwestern University, explains what hospitals need to consider when starting a new structural heart program. 

Thumbnail

New intravascular ultrasound study reveals ‘clear opportunity’ to help millions

“This is a moment for us to further our efforts in saving lives and saving limbs,” one Beth Israel Deaconess Medical Center expert said recently.

‘Saving lives and saving limbs’: New study of real-world CMS patients highlights the benefits of IVUS

The Smith Center for Outcomes Research in Cardiology examined real-world data from more than 700,000 CMS patients. The group's findings were presented during TCT 2021. 

Thumbnail

TMVR with transfemoral access a 'promising option,’ early data suggest

Researchers reported at TCT 2021 that survival was 100% after 30 days.

Thumbnail

5 years later, TAVR still delivering strong results for intermediate-risk patients

Researchers presented their findings at TCT 2021, noting that TAVR and surgery had similar mortality rates after five years. 

Thumbnail

TAVR more cost-effective than surgery for low-risk patients, new 2-year study confirms

The analysis, presented at TCT 2021, examined total costs after two years for more than 900 patients who underwent TAVR or SAVR.

Thumbnail

Patients amenable to interventional procedure for lowering blood pressure

The analysis, presented at TCT 2021, included input from 400 patients with high blood pressure. 

Displaying 81 - 88 of 112
Design by Adaptive Theme